Bleibel, Wasim K.

Wasim K. Bleibel

Associate
RELATED SERVICES

Wasim Bleibel represents pharmaceutical, biotechnology, beverage, software and energy companies in intellectual property litigation, intellectual property strategy and regulatory matters. He has significant experience representing clients in patent infringement litigation arising under the Hatch-Waxman Act and advising on related regulatory matters before the Food and Drug Administration, such as market exclusivity issues and Citizen Petitions. He also regularly advises clients on compliance with the laws and regulations enforced by the Federal Trade Commission and the Alcohol and Tobacco Tax and Trade Bureau.

Wasim Bleibel represents pharmaceutical, biotechnology, beverage, software and energy companies in intellectual property litigation, intellectual property strategy and regulatory matters. He has significant experience representing clients in patent infringement litigation arising under the Hatch-Waxman Act and advising on related regulatory matters before the Food and Drug Administration, such as market exclusivity issues and Citizen Petitions. He also regularly advises clients on compliance with the laws and regulations enforced by the Federal Trade Commission and the Alcohol and Tobacco Tax and Trade Bureau.

Wasim also has significant experience involving patent and trademark litigation and prosecution in other areas, including mechanical engineering, chemical formulations and medical devices.

Wasim also has experience in seed and agricultural biotechnology matters representing clients from seed producers to seed dealers and distributors, seedsmen's errors and omissions insurers.

Prior to his legal career, Wasim was a senior research scientist at the University of Chicago, where he worked to identify genetic determinants contributing to a patient's sensitivity to chemotherapeutic agents. His contributions resulted in his laboratory being the first to demonstrate that drug sensitivity to chemotherapy is a heritable genetic trait and that these responses vary between and amongst populations.

Wasim’s experience includes: 

  • Otsuka Pharmaceutical Co., Ltd. et al. v. Zydus Pharmaceuticals (USA) Inc. et al., (D. Del.) – Representing drug manufacturer in Hatch-Waxman litigation concerning oral formulations indicated for the treatment of major depressive disorder and schizophrenia
  • In re ʼ858 Patent Litigation, (S.D. Ind.) – Representing renewable energy company in patent litigation concerning the production of clean burning ethanolGS CleanTech Corp. v. Adkins Energy LLC (N.D. Ill.) – Representing renewable energy company on contract-based claims
  • Actelion Pharmaceuticals Ltd. v. Zydus Pharmaceuticals (USA) Inc., (D.N.J. Settled) – Represented drug manufacturer in Hatch-Waxman litigation concerning oral formulations indicated for the treatment of pulmonary arterial hypertension
  • Impax Laboratories v. Zydus Pharmaceuticals (USA) Inc. et al., (D.N.J. Settled) – Represented drug manufacturer in Hatch-Waxman litigation concerning oral formulations indicated for the treatment of Parkinson’s disease ‎
  • Sumitomo Dainippon Pharma Co., Ltd. v. Aurobindo Pharma Ltd., (D.N.J. Settled) – Represented drug manufacturer in Hatch-Waxman litigation concerning oral formulations indicated for the treatment of schizophrenia, depression and depression associated with bipolar disorder
  • Helsinn Healthcare S.A. v. Zydus Pharmaceuticals (USA) Inc. et al., (D.N.J. Settled) – Represented drug manufacturer in Hatch-Waxman litigation concerning injectable medication indicated for the treatment and prevention of chemotherapy-induced nausea and vomiting
  • Shire Development LLC, et al. v. Zydus Pharmaceuticals (USA) Inc. et al., (D. Del.) – Represented drug manufacturer in Hatch-Waxman litigation concerning oral formulations indicated for the treatment of ulcerative colitis
  • Feit Electric Company, Inc. v. Beacon Point Capital, LLC, ( N.D. Ill.) – Represented light bulb manufacturer Feit Electric Co., Inc., in declaratory judgment action involving a variety of electrical circuit and hardware patents
  • Hawk Technology Systems, LLC v. Gold Coast Group, Ltd., (N.D. Ill. Settled) – Represented defendant in patent infringement suit involving software and method patents
  • eDekka LLC v. Lovely Skin, Inc., (E.D. Tex. Settled) – Represented defendant Lovely Skin, Inc., in patent infringement action involving software patents
  • Endo Pharmaceuticals Inc. v. Roxane Laboratories, Inc., (S.D.N.Y.) – Represented generic drug manufacturer in Hatch-Waxman litigation concerning oral formulations of opioids indicated for the treatment of pain
  • Warner Chilcott Company LLC v. Zydus Pharmaceuticals (USA) Inc. et al., (D. Del. Settled) – Represented generic drug manufacturer in Hatch-Waxman litigation concerning oral formulations indicated for the treatment of ulcerative colitis
  • Depomed, Inc. v. Zydus Pharmaceuticals (USA) Inc. et al., (D.N.J. Settled) – Represented generic drug manufacturer in Hatch-Waxman litigation concerning oral formulations indicated for the treatment of Post-Herpetic Neuralgia
RELATED EXPERIENCE
RELATED EXPERIENCE
RELATED NEWS & EVENTS
CREDENTIALS
Education
  • J.D., John Marshall Law School, 2011
    Certificate in Intellectual Property Law
    Executive Lead Articles Editor
    Executive Director for the 2011 The John Marshall Review of Intellectual Property Law Symposium
  • Peking University, Beijing, China, 2009
    Comparative Intellectual Property Summer Abroad Program
  • B.A., Chemistry, Michigan State University, 2003
Bar Admissions
  • Illinois
Court Admissions
  • U.S. Supreme Court
  • U.S. Court of Appeals for the Federal Circuit
  • U.S. District Court for the Northern District of Illinois
Professional Affiliations
    • Pathfinder Program, The Leadership Council on Legal Diversity (2019)
    • The Richard Linn American Inn of Court
      • Barrister Member (2011-Present)
      • Treasurer (2016 - 2017)
      • Membership Chair (2014-2016)
      • Events Chair (2013-2014)
      Linn Inn Alliance Advisory Council
      • Liaison for the Richard Linn American Inn of Court (2018-Present)
    • Intellectual Property Law Association of Chicago
      • Board of Managers (2020-Present)
      • Young Members Committee
        • Chair (2014-2016)
        • Vice-Chair (2012-2014)
      • Biotechnology Committee
        • Co-Chair (2011-2013)
    • American Intellectual Property Law Association
    • International Trademark Association
Awards & Recognitions
    • Named, Illinois Super Lawyers® Rising Star, Intellectual Property Litigation (2014-2020)
    • Recipient, 5 Under 40 Award, Just the Beginning – A Pipeline Organization (2019)
    • Fellow, The Chicago Committee’s Pathway to Partnership Program (2019-2020)
Professional History
    • Associate, Locke Lord LLP
    • Associate, Levenfeld Pearlstein, LLC (2011-2012)
    • Senior Research Technician, The University of Chicago Department of Medicine (2003-2008)